(UroToday.com) Radiotherapy is a standard treatment for patients with localized prostate cancer. For patients with intermediate and high-risk disease, concurrent androgen deprivation therapy is commonly co-administered. However, there is an existing need to provide prognostication within this group of patients to allow for both treatment intensification and de-intensification. To this end, in a study presented during the Prostate Cancer – Advanced Disease Poster Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Jonathan Tward and colleagues evaluated the ability of the combined clinical cell-cycle risk score (CCR) to prognosticate the risk of prostate cancer metastasis in men receiving dose-escalated radiation therapy (RT) with or without androgen deprivation therapy (ADT).